Anti-cancer effects of newly developed chemotherapeutic agent, glycoconjugated palladium (II) complex, against cisplatin-resistant gastric cancer cells
2013 · BMC Cancer · 88 citations
https://doi.org/10.1186/1471-2407-13-237
Y
Yoshinori Mori
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
178
Papers
1.6K
Citations
22
h-index
43
i10-index
Yoshinori Mori is an academic researcher. The author has contributed to research in topics: Urological Disorders and Treatments & Pediatric Urology and Nephrology Studies & Urologic and reproductive health conditions. The author has an h-index of 22, co-authored 152 publications.
ORCID: 0000-0001-7199-4901Papers by this author
worksOncolytic reovirus combined with trastuzumab enhances antitumor efficacy through TRAIL signaling in human HER2-positive gastric cancer cells
2014 · Cancer Letters · 32 citations
https://doi.org/10.1016/j.canlet.2014.10.046
A phase II prospective study of the trastuzumab combined with 5-weekly S-1 and CDDP therapy for HER2-positive advanced gastric cancer
2016 · Cancer Chemotherapy and Pharmacology · 22 citations
https://doi.org/10.1007/s00280-016-3013-y
Phase II Prospective Study of Trastuzumab in Combination with S-1 and Oxaliplatin (SOX100) Therapy for HER2-Positive Advanced Gastric Cancer
2021 · Journal of Gastrointestinal Cancer · 4 citations
https://doi.org/10.1007/s12029-021-00711-0
Mesenchymal stem cell-derived small extracellular vesicles as a delivery vehicle of oncolytic reovirus
2025 · Life Sciences · 3 citations
https://doi.org/10.1016/j.lfs.2025.123489
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat